# EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture

> **NCT03955458** · PHASE4 · WITHDRAWN · sponsor: **Pacira Pharmaceuticals, Inc**

## Conditions studied

- Hip Fractures
- Intertrochanteric Fractures

## Interventions

- **DRUG:** EXPAREL
- **DRUG:** Ropivacaine
- **DRUG:** Bupivacaine Hydrochloride

## Key facts

- **NCT ID:** NCT03955458
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08-26
- **Primary completion:** 2020-05
- **Final completion:** 2020-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Recruitment difficulties
- **Last updated:** 2020-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03955458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03955458, "EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03955458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*